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The 2005 NIH Consensus Conference recommended assess-
ment of lung function in patients with chronic graft-versus-
host disease (cGVHD) by both pulmonary function tests
(PFTs) and assessment of pulmonary symptoms. The Chronic
GVHD Consortium has made serial collections of these
measures. Based on prior literature, we hypothesized that
the following subgroups would have higher non-relapse
mortality (NRM) or lower overall survival (OS): 1. Obstructive
lung disease; 2. Higher NIH lung score based on symptoms;
3. Higher Lung Function Score (LFS) based on PFTs; 4. Clinical
diagnosis of bronchiolitis obliterans syndrome (BOS).
Methods: Patients  2 years of age diagnosed with cGVHD
requiring systemic treatment  3 years after transplantation
were assessed every 3-6 months. Available PFT data were
abstracted, including FEV1, forced vital capacity (FVC) and
diffusing capacity of lung for carbon monoxide (DLCO).
Obstructive disease was deﬁned as a decreased FEV1 (tested
at <50%, <75%, <80%) and FEV1/FVC < 0.70. The NIH lung
score of 0-3 was based on the severity of pulmonary symp-
toms with exertion. The LFS was based on FEV1 and DLCO. A
clinical diagnosis of BOS was collected from the clinician-
completed data capture form. Cox regression models were ﬁt
for OS and NRM using a time-varying covariate model for
lung function measures and adjusting for patient and
transplant characteristics and non-lung cGVHD severity.
Results: There were 1591 visits used in this analysis, only
845 (50%) of the visits had recorded PFTs. Obstructive
physiology (FEV1<80%) was found in 184 visits and 54 visits
(6%) had FEV1 <50%. BOS was reported on 122 visits. Median
follow up time was 20.1 mo (range 2.9 e 47.7), and median
survival has not been reached. NIH lung score based on
symptoms was strongly correlated with NRM and OS
(Table 1). The NIH lung score correlated with Karnofsky
performance status (correlation ¼ -0.34), and both had
independent prognostic signiﬁcance in multivariate models.
None of the other measures including obstructive PFTs, LFS,
or the clinician's indicator of BOS, were signiﬁcantly associ-
ated with OS or NRM.
Conclusion: NIH clinical lung score of 0-3 based on pulmo-
nary symptoms is predictive of OS and NRM in patients with
cGVHD. PFT derived data, including the LFS and obstructive
physiology, and a clinical diagnosis of BOS are not associated
with OS or NRM. Our conclusions are limited by inconsistent
practices in performing PFTs.Table
Relationship between NIH Lung score based on symptoms and OS and NRM
Overall survival
overall
p
Value n HR, 95% CI
NIH Clinical Lung Score
based on Symptoms
(0-3)
0.007 0 1138 1.0
1 299 2.24 (1.35-3.72)
2 94 1.94 (0.90-4.19)
3 22 3.70 (1.04-13.17)457
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Graft versus host disease (GVHD) remains a principal barrier
to successful outcomes in allogeneic hematopoietic stem cell
transplant (HCT). Corticosteroids are the current standard
initial therapy for acute GVHD with complete responses of
25- 41%. New immunosuppressive strategies are required to
improve acute GVHD management and decrease toxicities of
immunosuppressive agents. We conclude that more effective
acute GVHD therapy may improve survival after allogeneic
HCT. The histone deacetylase inhibitor (HDACi) Vorinostat
has been shown to reduce serum levels of pro-inﬂammatory
cytokines with moderate efﬁcacy in acute GVHD in murine
pre-clinical HCT. We designed a protocol to test the safety
and potential efﬁcacy of a novel HDACi, LBH589, adminis-
tered to patients with acute GVHD within 72 hours of initi-
ation of glucocorticoid therapy (methylprednisolone 0.8 mg/
Kg/day IV or equivalent for at least 14 days) as ﬁrst line
therapy. LBH589 is a potent inhibitor of deacetylases and
HSP90 belonging to a structurally novel class of the cinnamic
hydroxamic acid class of compounds and is one of the most
potent HDACi.We have enrolled n¼9 subjects, median age 52
(39-62 yo), male n¼6/female n¼3, median onset of GVHD
day +34 post HCT (17-108 days) with overall GVHD grade II
(n¼6) or III (n¼3). The ﬁrst three patients were treated with
2.5 mg/m2 intravenously (IV) weekly x4 and a subsequent
subject was treated with 5mg/m2 IV weekly x 4 achieving
GVHD CR (n¼2) and PR (n¼2) on day +8 (after LBH589) and
all achieved GVHD CR on day+15. Due to manufacturer
discontinuation of the IV formulation, we amended the
protocol to use PO LBH589. Using 10mg PO thrice weekly 48
hours apart for 4 weeks, we treated 2 subjects which both
discontinued study drug due to GHVD progression within 7
days of LBH589. Due to safety concerns, the next group
received a reduced dose of 5 mg PO thrice weekly x 4 (Level
-1). Thus far we have accrued 4 subjects at this dose. By day
+8, the GVHD responsewas PR¼2 and CR¼2with all in GVHD
CR on day+15. Toxicities include reversible thrombocyto-
penia and neutropenia grade 1-2 (CTCAE 4) possibly related
to study drug. The overall GVHD CR rate of 80% by day +15 in
our initial cohort is encouraging, suggesting a role for HDACi
LBH589 as a tool to improve success of corticosteroids for
GVHD treatment. Correlative studies are planned to address
pharmacodynamics of LBH589 on inﬂammatory cytokines, to
correlate DAC enzymatic activity inhibition with clinicalNon-relapse mortality
p overall
p
Value n HR, 95% CI p
0.01 0 1132 1.0
0.002 1 292 2.34 (1.24-4.43) 0.009
0.09 2 93 2.55 (1.03-6.30) 0.04
0.04 3 22 5.17 (1.34-19.87) 0.02
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effect on T-cell subsets.Table 1
Risk Factor and IDO Activity Correlations for GVHD
Clinical Characteristics and GVHD
Risk Factors
GVHD
(n¼ 13)
No GVHD
(n ¼7)
P value
Age at HSCT, median (range) years 20 (2-69) 31 (1-49) 1.000*
Malignant disease, n (%) 10 (76.9) 7 (100.0) 0.521#
Non-malignant disease, n (%) 3 (23.1) 0
Malignant Disease Status at HSCT
CR1 3 (23.1) 3 (42.9) 0.415#
CR2 4 (30.8) 1 (14.3)
Active/Refractory 3 (23.1) 3 (42.9)
Conditioning Regimen
Myeloablative 7 (53.8) 5 (71.4) 0.484#
Reduced-intensity 6 (46.2) 2 (28.6)
HSCT Product
Bone marrow 6 (46.2) 1 (14.3) 0.199#
Peripheral Blood 5 (38.5) 3 (42.9)
Umbilical cord blood 2 (15.3) 3 (42.9)
HLA-Mismatch
0 9 (69.2) 4 (57.1) 0.207#
1 4 (30.8) 1 (14.3)
2 0 2 (28.6)
Unrelated Donor 9 (69.2) 5 (71.4) 1.000#
CD34+ cells/kg dose 3.63 x 106 3.19 x 106 0.757*
TNC cells/kg dose 4.81 x 108 4.18 x 108 0.699*
Post-HSCT Disease Relapse, n (%) 6 (46.2) 2 (28.6) 0.642#
Kyn/Trp (IDO) Ratio, median
(range)
1.55
(0.41-
15.15)
0.69
(0.16-2.06)
0.027*
AUC (Kyn/Trp IDO Ratio), median
(range)
43.20
(6.10-
666.80)
11.76
(8.03-35.49)
0.007*458
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Background: Grip strength and 2 minute walk test have
been suggested as elements of chronic graft-vs-host disease
(GVHD) assessment in clinical trials.
Methods: Using all available data (n¼584, 1,689 follow-up
visits, total of 2,273 visits) from a prospective observational
cohort study, we explored the relationship between grip
strength and 2 minute walk test and patient-reported
outcomes (Lee symptomscale, SF-36 and FACT-BMTquality of
life instruments, andHuman Activity Proﬁle, or HAP), chronic
GVHD severity (NIH global 0-3 score, clinician global 0-3
score, and patient-reported global 0-3 score) and mortality
(overall survival (OS) and non-relapse mortality (NRM)) in
multivariate analyses adjusted for signiﬁcant covariates.
Results: In multivariate analysis, 2 minute walk test was
signiﬁcantly ( P < .001) associated with intuitive domains of
the Lee Symptom Scale (overall, skin, lung, energy), while
grip strength was not. Excepting MCS (mental component
score), 2 minute walk test had signiﬁcant associationwith all
studied SF-36 domain and summary scores ( P < .001) and
FACT summary and domain scores ( P < .001). Both grip
strength and 2 minute walk test had signiﬁcant association
with FACT summary scores and HAP (maximum activity
score (MAS), and adjusted activity score (AAS)). In univariate
analysis using all visit data, 2minutewalk test had signiﬁcant
association with global chronic GVHD severity, as calculated
from organ scores, reported by clinicians, and reported by
patients ( P < .01). Patients with NIH global score of mild or
less and moderate achieved on average 20.7 and 15.3 feet,
respectively, greater distance covered compared to those
with NIH severe chronic GVHD. Conversely, grip strength had
no signiﬁcant association with any of these measures of
chronic GVHD. In time-varying multivariate models exam-
ining all data and adjusting for signiﬁcant covariates, 2
minute walk test was signiﬁcantly associated with both OS
and NRM (both P < .001), while no association was found for
grip strength.
Conclusions: Based on its consistent association with
symptom burden, QOL, chronic GVHD severity andmortality,
these data support the 2 minute walk test as a useful
measure in chronic GVHD assessment.459
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Background: Indoleamine 2,3-dioxygenase (IDO), the rate
limiting enzyme of tryptophan metabolism, in part mediates
allogeneic tolerance and may be important in allogeneic
HSCTand GVHD.
Objective: To prospectively evaluate in vivo IDO activity in
allogeneic HSCT recipients and test our hypothesis that IDO
activity is associated with acute GVHD.
Methods: Patients (>1 year-old) receiving allogeneic HSCT
were eligible. Plasma samples were collected at baseline and
days -3, 0, +7, 14, 21, 30, 45, 60, 100, 180, and 365 relative to
HSCT for tryptophan (Trp) and kynurenine (Kyn) quantiﬁca-
tion (mM) by high performance liquid chromatography.
Mann-Whitney rank tests were used to test associations
betweenKyn/Trp ratio (IDO activity) and area under the curve
(AUC) Kyn/Trp ratio and GVHD. Potential confounders were
tested for associationwith GVHDusing Fisher's exact tests (#)
or Mann-Whitney rank tests (*). Analyses were performed
using R (ver 2.12.1) and GraphPad Prism (ver 5.04).
Results: Twenty patients were evaluable for IDO activity and
GVHD. AMLwas themost common diagnosis (n¼ 9, 45%). All
patients engrafted atmean (SD) 17.2 (+/- 5) days. Acute GVHD
occurred in 13 (59.1%) patients: 10 were Grade I-II and 3were
Grade III.Median time toGVHDdiagnosiswas 46 days. Table 1
